<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596206</url>
  </required_header>
  <id_info>
    <org_study_id>LEFLU_R_01143</org_study_id>
    <secondary_id>Eudract#: 2007-000886-40</secondary_id>
    <nct_id>NCT00596206</nct_id>
  </id_info>
  <brief_title>Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis</brief_title>
  <acronym>LEADER</acronym>
  <official_title>Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To assess the efficacy response rate at 3-months of two dosing regimen of leflunomide in&#xD;
      DMARDs-naive patients presenting an early-RA using American College of Rheumatology 20%&#xD;
      response rate.&#xD;
&#xD;
      To assess the clinical efficacy at 1-month and 3-month using complementary efficacy criteria&#xD;
      (ACR 50, ACR 70, DAS 28) in each group of treatment, To assess the clinical and biological&#xD;
      safety using standard blood monitoring, TEAED and SAE in each group of treatment, To evaluate&#xD;
      treatment modifications; particularity leflunomide and concomitant use of AINS and&#xD;
      corticoids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy response rate using ACR 20 criteria in each initial dosing regimen group</measure>
    <time_frame>at 3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy response rate using ACR 50, ACR 70, DAS 28 efficacy criteria in each group of treatment</measure>
    <time_frame>at 1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological safety using standard blood monitoring, TEAED and SAE in each group of treatment</measure>
    <time_frame>From the Informed Consent Form (ICF) signature to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of acute phase response (ESR, CRP)</measure>
    <time_frame>At 1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and physician global assessment</measure>
    <time_frame>At 1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 questionnaire</measure>
    <time_frame>At 1 and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of leflunomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg of leflunomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of active rheumatoid arthritis in the previous 6 months (according to the&#xD;
             ACR guidelines)&#xD;
&#xD;
          -  Must have active disease to be initiated by DMARDs (Disease Modifying Anti-Rheumatic&#xD;
             Drugs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presenting or having a history of other inflammatory joint disease&#xD;
&#xD;
          -  Patient with ongoing or previous Stevens-Johnson syndrome, toxic epidermal necrolysis&#xD;
             or erythema multiforme&#xD;
&#xD;
          -  Patient with significantly impaired bone marrow function or significant anaemia,&#xD;
             leucopenia or thrombocytopenia due to causes or other than active rheumatoid arthritis&#xD;
&#xD;
          -  Persistent infection or severe infection within 3 months before enrollment,&#xD;
&#xD;
          -  Uncontrolled hypertension, uncontrolled diabetes, unstable ischemic heart disease,&#xD;
             active inflammatory bowel disease, active peptic ulcer disease, terminal illness or&#xD;
             other medical condition which, in the opinion of the investigator, would put the&#xD;
             patient at risk to participate in the study,&#xD;
&#xD;
          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major&#xD;
             systemic disease making implementation of the protocol or interpretation of the study&#xD;
             results difficult&#xD;
&#xD;
          -  Severe hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome)&#xD;
             with serum albumin &lt; 3.0 g/dl&#xD;
&#xD;
          -  Moderate or severe impairment of renal function, as known by serum creatinine &gt; 133&#xD;
             mcmol/L (or 1.5 mg/dl)&#xD;
&#xD;
          -  Patient with history of recent and clinically significant drug or alcohol abuse&#xD;
&#xD;
          -  Impairment of liver function or persisting ALT (SGPT) elevations of more than 2-fold&#xD;
             the upper limit of normal&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Women of childbearing potential, except if they fulfill specific conditions,&#xD;
&#xD;
          -  Men wishing to father children during the course of the study or within the 24 months&#xD;
             thereafter (or 3 month with the washout procedure)&#xD;
&#xD;
          -  Patient with a congenital or acquired severe immuno-deficiency, a history of cancer or&#xD;
             lymphoproliferative disease, or any patient who has received total lymphoid&#xD;
             irradiation&#xD;
&#xD;
          -  Known HIV positive status&#xD;
&#xD;
          -  Known positive serology for hepatitis B or C&#xD;
&#xD;
          -  Patient with hypersensitivity to any of the excipients in the tablets of leflunomide&#xD;
&#xD;
          -  Previous therapy at any time with:&#xD;
&#xD;
               -  any DMARD including methotrexate, oral or injectable gold salts, chloroquine,&#xD;
                  hydroxychloroquine, ciclosporin, azathioprine, methotrexate, sulfasalazine&#xD;
&#xD;
               -  D penicillamine&#xD;
&#xD;
               -  alkylating agents, e.g., cyclophosphamide, chlorambucil, biological agents, e.g.,&#xD;
                  interferon, monoclonal antibodies, growth factor, cytokines&#xD;
&#xD;
               -  any investigational drug&#xD;
&#xD;
               -  any antimetabolites&#xD;
&#xD;
               -  any opiates&#xD;
&#xD;
          -  Therapy within the previous 4 weeks with:&#xD;
&#xD;
               -  oral corticosteroids exceeding a prednisolone equivalent of 10 mg/day&#xD;
&#xD;
               -  parenteral or intra-articular corticoid injection&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Perdriset</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>October 11, 2010</last_update_submitted>
  <last_update_submitted_qc>October 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>Sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

